The previous published literature has shown positive therapeutic impact on various malignancies in the use of EZH2 inhibitors when they were combined with other chemotherapeutic drugs; for instance, in prostate [92], lung [93], ovarian [94], and breast cancer [95]. Here, EZH2 is linked to breast carcinoma.